Suzhou, China · Founded 2015 · Privately Held (backing)
Provider of gene and cell therapy contract research services intended to assist drug development companies. Ubrigene is based in Suzhou, China and was founded in 2015. Its last reported valuation was $50.8 million in Dec 2020. It has raised $143 million.
Last reported valuation
$50.8M
Oct 2026
Priced at
—
Total raised
$142.9M
Last round
—
Cap table — not yet on record
Ubrigene's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Ubrigene with a free account
·The complete investor list: 18 names
·Watch Ubrigene: the Monday email on marks, rounds and moves
